Compositions and methods for treating cancer
View Patent ↗Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.
1. A composition comprising:
(i) a compound of Formula I:
wherein:
R 1 and R 2 is F, and the other is selected from H and F;
R 3 and R 4 are H;
where—is a covalent bond or absent, and R 4 is absent when—is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof;
(ii) a cytidine deaminase (CDA) substrate drug; and
(iii) at least one additional pharmaceutical agent, wherein the pharmaceutical agent is selected from an anti-emetic, an agent that increases appetite, a cytotoxic or chemotherapeutic agent, and an agent that relieves pain;
as a combination for simultaneous, separate, or sequential administration.
2. The composition of claim 1 , wherein the CDA substrate drug is selected from the group consisting of decitabine, 5-azacytidine, gemcitabine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, and cytochlor.
3. The composition of claim 2 , wherein the CDA substrate drug is 5-azacytidine, gemcitabine, or ara-C.
4. The composition of claim 2 , wherein the CDA substrate drug is decitabine.
5. The composition of claim 1 , wherein the compound of Formula I is a compound of Formula VIII:
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
6. The composition of claim 1 , wherein the pharmaceutical agent is selected from a cytotoxic or chemotherapeutic agent.
7. The composition of claim 4 , wherein the compound of Formula I is a compound of Formula VIII:
or a pharmaceutically acceptable salt , a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
8. A method for treating cancer in a mammal in need thereof, comprising:
(i) administering to said mammal a compound of Formula 1:
wherein:
one of R 1 and R 2 is F, and the other is selected from H and F;
R 3 and R 4 are H;
where—is a covalent bond or absent, and R 4 is absent when—is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof;
(ii) administering to said mammal a CDA substrate drug; and
(iii) administering to said mammal at least one additional pharmaceutical agent, wherein the pharmaceutical agent is selected from an anti-emetic, an agent that increases appetite, a cytotoxic or chemotherapeutic agent, and an agent that relieves pain.
9. The method of claim 8 , wherein the CDA substrate drug is selected from the group consisting of decitabine, 5-azacytidine, gemcitabine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, and cytochlor.
10. The method of claim 8 , wherein the CDA substrate drug is 5-azacytidine, gemcitabine, or ara-C.
11. The method of claim 8 , wherein the CDA substrate drug is decitabine.
12. The method of claim 8 , wherein the pharmaceutical agent is selected from a cytotoxic or chemotherapeutic agent.
13. The method of claim 8 , wherein the cancer is selected from hematological cancers and solid cancers.
14. The method of claim 8 , wherein the cancer is a hematological cancer selected from myelodysplastic syndrome and leukemia.
15. The method of claim 8 , wherein the cancer is a solid cancer selected from the group consisting of pancreatic cancer, ovarian cancer, peritoneal cancer, metastatic breast cancer, bladder cancer, squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, gynecological cancer, fallopian tube carcinoma, liver cancer, hepatocellular carcinoma, lung cancer, cervical carcinoma, genitourinary tract cancer, and gastrointestinal cancer.
16. The method of claim 8 , wherein the compound of Formula I is a compound of Formula VIII:
or a pharmaceutically acceptable salt , a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
17. The method of claim 8 , wherein the compound is administered at substantially the same time with the CDA substrate drug, prior to the CDA substrate drug or after the CDA substrate drug.
18. The method of claim 8 , wherein the compound and the CDA substrate drug are administered in a single unit dosage form or in multiple, separate unit dosage forms.
19. The method of claim 11 , wherein the compound of Formula I is a compound of Formula VIII:
or a pharmaceutically acceptable salt , a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof.
20. A pharmaceutical composition comprising the composition of claim 1 and a pharmaceutically acceptable excipient.
21. The method of claim 14 , wherein the leukemia is acute myeloid leukemia or chronic myeloid leukemia.
22. The method of claim 15 , wherein the lung cancer is non small cell lung cancer.
23. A composition comprising:
(i) a compound of Formula I:
wherein:
one of R 1 and R 2 is F and the other is H;
one of R 3 and R 4 is H, and the other is selected from H and OH;
where —is a covalent bond or absent, and R 4 is absent when —is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof;
(ii) a cytidine deaminase (CDA) substrate drug; and
(iii) at least one additional pharmaceutical agent, wherein the pharmaceutical agent is selected from an anti-emetic, an agent that increases appetite, a cytotoxic or chemotherapeutic agent, and an agent that relieves pain;
as a combination for simultaneous, separate, or sequential administration.
24. The composition of claim 23 , wherein the CDA substrate drug is selected from the group consisting of decitabine, 5-azacytidine, gemcitabine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, and cytochlor.
25. The composition of claim 24 , wherein the CDA substrate drug is 5-azacytidine, gemcitabine, or ara-C.
26. The composition of claim 24 , wherein the CDA substrate drug is decitabine.
27. The composition of claim 23 , wherein the pharmaceutical agent is selected from a cytotoxic or chemotherapeutic agent.
28. A method for treating cancer in a mammal in need thereof, comprising:
(i) administering to said mammal a compound of Formula 1:
wherein:
one of R 1 and R 2 is F and the other is H;
one of R 3 and R 4 is H, and the other is selected from H and OH;
where—is a covalent bond or absent, and R 4 is absent when—is a covalent bond;
or a pharmaceutically acceptable salt, a C 1-6 alkyl ester, or a C 2-6 alkenyl ester thereof;
(ii) administering to said mammal a CDA substrate drug; and
(iii) administering to said mammal at least one additional pharmaceutical agent, wherein the pharmaceutical agent is selected from an anti-emetic, an agent that increases appetite, a cytotoxic or chemotherapeutic agent, and an agent that relieves pain.
29. The method of claim 28 , wherein the CDA substrate drug is selected from the group consisting of decitabine, 5-azacytidine, gemcitabine, ara-C, tezacitabine, 5-fluoro-2′-deoxycytidine, and cytochlor.
30. The method of claim 28 , wherein the CDA substrate drug is 5-azacytidine, gemcitabine, or ara-C.
31. The method of claim 28 , wherein the CDA substrate drug is decitabine.
32. The method of claim 28 , wherein the pharmaceutical agent is selected from a cytotoxic or chemotherapeutic agent.
33. The method of claim 28 , wherein the cancer is selected from hematological cancers and solid cancers.
34. The method of claim 28 , wherein the cancer is a hematological cancer selected from myelodysplastic syndrome and leukemia.
35. The method of claim 28 , wherein the cancer is a solid cancer selected from the group consisting of pancreatic cancer, ovarian cancer, peritoneal cancer, metastatic breast cancer, bladder cancer, squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, gynecological cancer, fallopian tube carcinoma, liver cancer, hepatocellular carcinoma, lung cancer, cervical carcinoma, genitourinary tract cancer, and gastrointestinal cancer.
36. The method of claim 28 , wherein the compound is administered at substantially the same time with the CDA substrate drug, prior to the CDA substrate drug or after the CDA substrate drug.
37. The method of claim 28 , wherein the compound and the CDA substrate drug are administered in a single unit dosage form or in multiple, separate unit dosage forms.
38. A pharmaceutical composition comprising the composition of claim 23 and a pharmaceutically acceptable excipient.
39. The method of claim 34 , wherein the leukemia is acute myeloid leukemia or chronic myeloid leukemia.
40. The method of claim 35 , wherein the lung cancer is non small cell lung cancer.